Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options ...

The hope is the therapy can effectively target cancerous cells at relatively small doses while minimizing side effects.

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

Dr Mohammad Mahmoud shares anticipated updates on evolving local treatments, PSMA-based therapies, and impactful genetic studies.

The first patient in a phase 2 clinical trial evaluating 67Cu-SAR-bisPSMA for patients with metastatic castration-resistant ...

Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate ...

The phase 2a LEGION-100 trial seeks to evaluate the safety and effectiveness of the SYNC-T/SV-102 combination therapy for treating metastatic castration-resistant prostate cancer (mCRPC) and to ...

New research shows distant-stage prostate cancer increased 6.7% annually across California between 2011 and 2021, while mortality rates have plateaued since 2012 after years of decline.

The sector has seen billions in merger and acquisition activity in recent years; a September 2024 analysis by Insight ...

The study advanced beyond a one-size-fits-all model by developing both a global XGBoost classifier and cancer-type-specific ...

Medically reviewed by Jamin Brahmbhatt, MD The treatment of metastatic castration-resistant prostate cancer (mCRPC) involves ...

Medically reviewed by Jamin Brahmbhatt, MD Metastatic castration-resistant prostate cancer (mCRPC) is a type of advanced ...